Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05935150 | Omission of SLNB in CN0 Early Breast Cancer | recruiting | N/A | 311 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06464913 | Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction | recruiting | Phase 2 | 152 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Oct 15, 2024 |
| clinicaltrials |
| NCT06611306 | BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.(BEAT-Breast) | not yet recruiting | N/A | 42 | Imperial College LondonOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06637202 | Swebcg 91:A RT. Breast Conserving Surgery With or Without Radiotherapy for Breast Cancer Patients | active not recruiting | N/A | 1,187 | Region SkaneOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06641544 | The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer(IFANS) | recruiting | Phase 4 | 200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06642948 | AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial(AiRE-MS) | recruiting | N/A | 80 | Fudan UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06632886 | AI-Assisted Non-Contrast CT for Multi-Cancer Screening | recruiting | N/A | 1,000,000 | Guo ShiWeiOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06633601 | MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer | recruiting | Phase 1 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT02647385 | Pain Control in Breast Surgery: Analgesia, Opioid Consumption and Inflammatory Response Evaluation | active not recruiting | N/A | 50 | Hospital Sirio-LibanesOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06630962 | Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care(COST-FIN) | recruiting | N/A | 200 | Northwestern UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT05594095 | SNF Platform Study of HR+/ HER2-advanced Breast Cancer | recruiting | Phase 2 | 620 | Fudan UniversityOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT05878964 | Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.(SkinHealth) | recruiting | — | 420 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06624917 | Assessment of Oncological Safety, Quality of Life, and Environmental Impact of the Green Breast Surgery Protocol(BuGs) | recruiting | N/A | 110 | University of Rome Tor VergataOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT06625879 | The Mid-point Transverse Process to Pleura Block Versus Serratus Anterior Plane Block for Postoperative Analgesia After Modified Radical Mastectomy((SAPB) (MTPB)) | not yet recruiting | N/A | 30 | Ain Shams UniversityOTHER | 0 | Oct 3, 2024 | clinicaltrials |
| NCT06622954 | Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients(PROTECT-COR) | recruiting | N/A | 32 | Erasmus Medical CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06622967 | KNUCH CadAI-B-1(KCB-1) | active not recruiting | N/A | 100 | JeeYeon LeeOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05241405 | Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer(QISEIN) | recruiting | N/A | 354 | Centre Francois BaclesseOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04258280 | Improving Genetic Counseling for BRCA+ Mothers(PCS IV) | recruiting | N/A | 200 | Georgetown UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06026631 | Lipidomic Characterization in Non-metastatic Breast Cancer Women Undergoing Surgery: a Pilot Study.(BreCaLip) | active not recruiting | N/A | 65 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06185972 | Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast Cancer | recruiting | Phase 2 | 200 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06299202 | Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy(CERePred) | recruiting | N/A | 100 | Hospices Civils de LyonOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06615466 | Super-Hypofractionated Partial Breast Irradiation | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06613373 | An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer | not yet recruiting | Phase 4 | 30 | Jiangsu Famous Medical Technology Co., Ltd.INDUSTRY | 0 | Sep 25, 2024 | clinicaltrials |
| NCT04344496 | East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction | recruiting | — | 2,000 | National Taiwan University HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06606535 | ENDO-BRAIN: Effects of Endocrine Adjuvant Therapy with Aromatase Inhibitors on the Cognitive Function of Breast Cancer Patients(ENDO-BRAIN) | recruiting | — | 60 | Ospedale Policlinico San MartinoOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04547907 | A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 688 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06489158 | Observation of Exhaled VOC Biomarkers Characteristics in Admitted Women with Breast Ultrasound BI-RADS 4 Grade | recruiting | — | 168 | Peking Union Medical College HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06605521 | To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients | recruiting | — | 300 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04539496 | A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 402 | Sihuan Pharmaceutical Holdings Group Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04875351 | Breast Cancer Index (BCI) Registry | active not recruiting | — | 3,465 | Biotheranostics, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05019690 | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 29 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05772390 | Partial Breast Re-irradiation in Women in Women with Locally Recurrent Breast Cancer Previously Treated with Conservative Surgery and Whole Breast Irradiation(PBReI) | recruiting | Phase 2 | 68 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05841186 | Correlation of Timing of Pegfilgrastim Administration and PIBP. | recruiting | N/A | 156 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06272799 | Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.(ATD) | recruiting | — | 160 | Regina Elena Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06342037 | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial(TONIC-3) | recruiting | Phase 2 | 60 | The Netherlands Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06378944 | Selective Sentinella Lymph Node Biopsy with Indocyanine Green in Patients with Breast Cancer(INSEAN) | recruiting | — | 15,000 | Omphis FoundationOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06559696 | Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy | recruiting | Phase 3 | 722 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06575049 | Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery | not yet recruiting | — | 60 | Seoul National University HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06586866 | JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases | not yet recruiting | Phase 2 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06591039 | A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China | recruiting | — | 20,000 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592560 | Asprosin in Breast Cancer | not yet recruiting | — | 84 | Marina Hanna Thabet GhobrialOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06595966 | Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery | recruiting | — | 80 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06331169 | Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer | recruiting | Phase 1 | 42 | Fudan UniversityOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06578286 | ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | not yet recruiting | Phase 2 | 44 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06578299 | Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer | not yet recruiting | Phase 4 | 100 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT02802553 | Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions | active not recruiting | N/A | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT03827317 | HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer | recruiting | N/A | 24 | Imperial College LondonOTHER | 1 | Aug 26, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Oct 15, 2024source: clinicaltrials